HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system.

Abstract
The tumor necrosis factor (TNF)-related apoptosis-inducing ligand- receptor (TRAIL-R) family has emerged as a key mediator of cell fate and survival. Ligation of TRAIL ligand to TRAIL-R1 or TRAIL-R2 initiates the extrinsic apoptotic pathway characterized by the recruitment of death domains, assembly of the death-inducing signaling complex (DISC), caspase activation and ultimately apoptosis. Conversely the decoy receptors TRAIL-R3 and TRAIL-R4, which lack the pro-apoptotic death domain, function to dampen the apoptotic response by competing for TRAIL ligand. The tissue restricted expression of the decoy receptors on normal but not cancer cells provides a therapeutic rational for the development of selective TRAIL-mediated anti-tumor therapies. Recent clinical trials using agonistic antibodies against the apoptosis-inducing TRAIL receptors or recombinant TRAIL have been promising; however the number of patients in complete remission remains stubbornly low. The mechanisms of TRAIL resistance are relatively unexplored but may in part be due to TRAIL-R down-regulation or shedding of TRAIL-R by tumor cells. Therefore a better understanding of the mechanisms underlying TRAIL resistance is required. The ubiquitin-proteasome system (UPS) has been shown to regulate TRAIL-R members suggesting that pharmacological inhibition of the UPS may be a novel strategy to augment TRAIL-based therapies and increase efficacies. We recently identified b-AP15 as an inhibitor of proteasome deubiquitinase (DUB) activity. Interestingly, exposure of tumor cell lines to b-AP15 resulted in increased TRAIL-R2 expression and enhanced sensitivity to TRAIL-mediated apoptosis and cell death in vitro and in vivo. In conclusion, targeting the UPS may represent a novel strategy to increase the cell surface expression of pro-apoptotic TRAIL-R on cancer cells and should be considered in clinical trials targeting TRAIL-receptors in cancer patients.
AuthorsDhifaf Sarhan, Padraig D'Arcy, Andreas Lundqvist
JournalInternational journal of molecular sciences (Int J Mol Sci) Vol. 15 Issue 10 Pg. 18557-73 (Oct 14 2014) ISSN: 1422-0067 [Electronic] Switzerland
PMID25318057 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Receptors, TNF-Related Apoptosis-Inducing Ligand
  • Tumor Necrosis Factor-alpha
  • Ubiquitin
  • Proteasome Endopeptidase Complex
Topics
  • Animals
  • Apoptosis (drug effects)
  • Gene Expression Regulation, Neoplastic (drug effects)
  • Humans
  • Molecular Targeted Therapy
  • Neoplasms (drug therapy, genetics, metabolism)
  • Proteasome Endopeptidase Complex (metabolism)
  • Receptors, TNF-Related Apoptosis-Inducing Ligand (genetics, metabolism)
  • Tumor Necrosis Factor-alpha (metabolism)
  • Ubiquitin (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: